nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—Pimecrolimus—atopic dermatitis	0.206	0.5	CrCtD
Sirolimus—Tacrolimus—atopic dermatitis	0.206	0.5	CrCtD
Sirolimus—MTOR—Pimecrolimus—atopic dermatitis	0.0738	0.294	CbGbCtD
Sirolimus—FKBP1A—Pimecrolimus—atopic dermatitis	0.0638	0.254	CbGbCtD
Sirolimus—Pimecrolimus—Tacrolimus—atopic dermatitis	0.0443	0.167	CrCrCtD
Sirolimus—Everolimus—Pimecrolimus—atopic dermatitis	0.0443	0.167	CrCrCtD
Sirolimus—Temsirolimus—Pimecrolimus—atopic dermatitis	0.0443	0.167	CrCrCtD
Sirolimus—Everolimus—Tacrolimus—atopic dermatitis	0.0443	0.167	CrCrCtD
Sirolimus—Temsirolimus—Tacrolimus—atopic dermatitis	0.0443	0.167	CrCrCtD
Sirolimus—Tacrolimus—Pimecrolimus—atopic dermatitis	0.0443	0.167	CrCrCtD
Sirolimus—MTOR—Tacrolimus—atopic dermatitis	0.0439	0.175	CbGbCtD
Sirolimus—FKBP1A—Tacrolimus—atopic dermatitis	0.038	0.151	CbGbCtD
Sirolimus—CYP3A7—Tacrolimus—atopic dermatitis	0.00368	0.0146	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Tacrolimus—atopic dermatitis	0.00368	0.0146	CbGbCtD
Sirolimus—CYP3A5—Tacrolimus—atopic dermatitis	0.00276	0.011	CbGbCtD
Sirolimus—CYP3A4—Pimecrolimus—atopic dermatitis	0.00181	0.0072	CbGbCtD
Sirolimus—ABCB1—Tacrolimus—atopic dermatitis	0.0018	0.00715	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Hydrocortisone—atopic dermatitis	0.0015	0.00596	CbGbCtD
Sirolimus—CYP3A7—Hydrocortisone—atopic dermatitis	0.0015	0.00596	CbGbCtD
Sirolimus—ABCB1—Loratadine—atopic dermatitis	0.00131	0.00523	CbGbCtD
Sirolimus—ABCB1—Methylprednisolone—atopic dermatitis	0.0012	0.00479	CbGbCtD
Sirolimus—CYP3A5—Hydrocortisone—atopic dermatitis	0.00112	0.00447	CbGbCtD
Sirolimus—CYP3A4—Tacrolimus—atopic dermatitis	0.00108	0.00428	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Dexamethasone—atopic dermatitis	0.000931	0.00371	CbGbCtD
Sirolimus—CYP3A7—Dexamethasone—atopic dermatitis	0.000931	0.00371	CbGbCtD
Sirolimus—CYP3A4—Loratadine—atopic dermatitis	0.000787	0.00314	CbGbCtD
Sirolimus—ABCB1—Betamethasone—atopic dermatitis	0.000781	0.00311	CbGbCtD
Sirolimus—ABCB1—Prednisolone—atopic dermatitis	0.000771	0.00307	CbGbCtD
Sirolimus—ABCB1—Hydrocortisone—atopic dermatitis	0.000731	0.00291	CbGbCtD
Sirolimus—ABCB1—Prednisone—atopic dermatitis	0.000728	0.0029	CbGbCtD
Sirolimus—CYP3A4—Methylprednisolone—atopic dermatitis	0.00072	0.00287	CbGbCtD
Sirolimus—CYP3A5—Dexamethasone—atopic dermatitis	0.000698	0.00278	CbGbCtD
Sirolimus—EIF4E—Temsirolimus—Pimecrolimus—atopic dermatitis	0.000584	0.5	CbGdCrCtD
Sirolimus—EIF4E—Temsirolimus—Tacrolimus—atopic dermatitis	0.000584	0.5	CbGdCrCtD
Sirolimus—CYP3A4—Triamcinolone—atopic dermatitis	0.000546	0.00217	CbGbCtD
Sirolimus—CYP3A4—Betamethasone—atopic dermatitis	0.000468	0.00186	CbGbCtD
Sirolimus—CYP3A4—Prednisolone—atopic dermatitis	0.000462	0.00184	CbGbCtD
Sirolimus—ABCB1—Dexamethasone—atopic dermatitis	0.000455	0.00181	CbGbCtD
Sirolimus—CYP3A4—Hydrocortisone—atopic dermatitis	0.000438	0.00174	CbGbCtD
Sirolimus—CYP3A4—Prednisone—atopic dermatitis	0.000436	0.00174	CbGbCtD
Sirolimus—CYP3A4—Dexamethasone—atopic dermatitis	0.000272	0.00108	CbGbCtD
Sirolimus—FGF2—Innate Immune System—TLR2—atopic dermatitis	1.75e-05	0.0011	CbGpPWpGaD
Sirolimus—FGF2—Immune System—KIF3A—atopic dermatitis	1.75e-05	0.0011	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—STAT6—atopic dermatitis	1.73e-05	0.00108	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—CD79A—atopic dermatitis	1.72e-05	0.00108	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—FCER2—atopic dermatitis	1.71e-05	0.00107	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—SLC11A1—atopic dermatitis	1.7e-05	0.00107	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CCL17—atopic dermatitis	1.67e-05	0.00105	CbGpPWpGaD
Sirolimus—FGF2—Fc epsilon receptor (FCERI) signaling—MAPK8—atopic dermatitis	1.66e-05	0.00104	CbGpPWpGaD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—atopic dermatitis	1.63e-05	0.00102	CbGpPWpGaD
Sirolimus—MTOR—Immune System—DEFB1—atopic dermatitis	1.62e-05	0.00102	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—NGF—atopic dermatitis	1.62e-05	0.00102	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCL22—atopic dermatitis	1.59e-05	0.000995	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—CD79A—atopic dermatitis	1.58e-05	0.000991	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—MAPK8—atopic dermatitis	1.56e-05	0.00098	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CCR3—atopic dermatitis	1.5e-05	0.000941	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—KIF3A—atopic dermatitis	1.49e-05	0.000936	CbGpPWpGaD
Sirolimus—FGF2—Immune System—STAT6—atopic dermatitis	1.49e-05	0.000933	CbGpPWpGaD
Sirolimus—FGF2—Signaling by Insulin receptor—IL6—atopic dermatitis	1.49e-05	0.000932	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—SLC11A1—atopic dermatitis	1.47e-05	0.000924	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—CASP8—atopic dermatitis	1.45e-05	0.000912	CbGpPWpGaD
Sirolimus—MTOR—BDNF signaling pathway—MAPK8—atopic dermatitis	1.45e-05	0.000912	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CARD11—atopic dermatitis	1.45e-05	0.000907	CbGpPWpGaD
Sirolimus—Discomfort—Prednisolone—atopic dermatitis	1.44e-05	0.000263	CcSEcCtD
Sirolimus—Angioedema—Triamcinolone—atopic dermatitis	1.44e-05	0.000263	CcSEcCtD
Sirolimus—Haemoglobin—Prednisone—atopic dermatitis	1.44e-05	0.000262	CcSEcCtD
Sirolimus—MTOR—Innate Immune System—CASP1—atopic dermatitis	1.44e-05	0.000901	CbGpPWpGaD
Sirolimus—Angioedema—Methylprednisolone—atopic dermatitis	1.43e-05	0.000262	CcSEcCtD
Sirolimus—MTOR—Disease—GLB1—atopic dermatitis	1.43e-05	0.000897	CbGpPWpGaD
Sirolimus—Haemorrhage—Prednisone—atopic dermatitis	1.43e-05	0.000261	CcSEcCtD
Sirolimus—Myalgia—Hydrocortisone—atopic dermatitis	1.42e-05	0.00026	CcSEcCtD
Sirolimus—Hallucination—Prednisone—atopic dermatitis	1.42e-05	0.00026	CcSEcCtD
Sirolimus—Malaise—Triamcinolone—atopic dermatitis	1.42e-05	0.000259	CcSEcCtD
Sirolimus—Anxiety—Hydrocortisone—atopic dermatitis	1.42e-05	0.000259	CcSEcCtD
Sirolimus—Malaise—Methylprednisolone—atopic dermatitis	1.42e-05	0.000259	CcSEcCtD
Sirolimus—MTOR—IRS-mediated signalling—IL6—atopic dermatitis	1.41e-05	0.000887	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCL27—atopic dermatitis	1.41e-05	0.000887	CbGpPWpGaD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—atopic dermatitis	1.41e-05	0.000258	CcSEcCtD
Sirolimus—Syncope—Triamcinolone—atopic dermatitis	1.41e-05	0.000258	CcSEcCtD
Sirolimus—EIF4E—Immune System—IL18—atopic dermatitis	1.41e-05	0.000885	CbGpPWpGaD
Sirolimus—Syncope—Methylprednisolone—atopic dermatitis	1.41e-05	0.000257	CcSEcCtD
Sirolimus—Discomfort—Hydrocortisone—atopic dermatitis	1.41e-05	0.000257	CcSEcCtD
Sirolimus—Connective tissue disorder—Prednisone—atopic dermatitis	1.4e-05	0.000257	CcSEcCtD
Sirolimus—Anaphylactic shock—Prednisolone—atopic dermatitis	1.4e-05	0.000255	CcSEcCtD
Sirolimus—Oedema—Prednisolone—atopic dermatitis	1.4e-05	0.000255	CcSEcCtD
Sirolimus—Vomiting—Tacrolimus—atopic dermatitis	1.39e-05	0.000254	CcSEcCtD
Sirolimus—EIF4E—Immune System—CD8A—atopic dermatitis	1.39e-05	0.000872	CbGpPWpGaD
Sirolimus—Loss of consciousness—Triamcinolone—atopic dermatitis	1.38e-05	0.000253	CcSEcCtD
Sirolimus—Loss of consciousness—Methylprednisolone—atopic dermatitis	1.38e-05	0.000252	CcSEcCtD
Sirolimus—Rash—Tacrolimus—atopic dermatitis	1.38e-05	0.000252	CcSEcCtD
Sirolimus—Dermatitis—Tacrolimus—atopic dermatitis	1.38e-05	0.000252	CcSEcCtD
Sirolimus—MTOR—IRS-related events—IL6—atopic dermatitis	1.38e-05	0.000863	CbGpPWpGaD
Sirolimus—Shock—Prednisolone—atopic dermatitis	1.37e-05	0.000251	CcSEcCtD
Sirolimus—Cough—Triamcinolone—atopic dermatitis	1.37e-05	0.000251	CcSEcCtD
Sirolimus—Headache—Tacrolimus—atopic dermatitis	1.37e-05	0.00025	CcSEcCtD
Sirolimus—Anaphylactic shock—Hydrocortisone—atopic dermatitis	1.36e-05	0.000249	CcSEcCtD
Sirolimus—Oedema—Hydrocortisone—atopic dermatitis	1.36e-05	0.000249	CcSEcCtD
Sirolimus—MTOR—IRS-related events triggered by IGF1R—IL6—atopic dermatitis	1.36e-05	0.000855	CbGpPWpGaD
Sirolimus—Tachycardia—Prednisolone—atopic dermatitis	1.36e-05	0.000249	CcSEcCtD
Sirolimus—Hypertension—Triamcinolone—atopic dermatitis	1.36e-05	0.000248	CcSEcCtD
Sirolimus—Hypertension—Methylprednisolone—atopic dermatitis	1.36e-05	0.000248	CcSEcCtD
Sirolimus—Infection—Hydrocortisone—atopic dermatitis	1.36e-05	0.000248	CcSEcCtD
Sirolimus—Hyperhidrosis—Prednisolone—atopic dermatitis	1.35e-05	0.000247	CcSEcCtD
Sirolimus—FKBP1A—Signaling Pathways—CMA1—atopic dermatitis	1.35e-05	0.000846	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CCL11—atopic dermatitis	1.35e-05	0.000846	CbGpPWpGaD
Sirolimus—Shock—Hydrocortisone—atopic dermatitis	1.34e-05	0.000245	CcSEcCtD
Sirolimus—Myalgia—Triamcinolone—atopic dermatitis	1.34e-05	0.000245	CcSEcCtD
Sirolimus—Nervous system disorder—Hydrocortisone—atopic dermatitis	1.34e-05	0.000245	CcSEcCtD
Sirolimus—MTOR—Signaling by NGF—NFKBIA—atopic dermatitis	1.34e-05	0.000839	CbGpPWpGaD
Sirolimus—Myalgia—Methylprednisolone—atopic dermatitis	1.34e-05	0.000244	CcSEcCtD
Sirolimus—Arthralgia—Methylprednisolone—atopic dermatitis	1.34e-05	0.000244	CcSEcCtD
Sirolimus—EIF4E—Signaling Pathways—NPS—atopic dermatitis	1.34e-05	0.000838	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TAC1—atopic dermatitis	1.34e-05	0.000838	CbGpPWpGaD
Sirolimus—MTOR—Insulin Signaling—MAPK8—atopic dermatitis	1.34e-05	0.000838	CbGpPWpGaD
Sirolimus—Anxiety—Methylprednisolone—atopic dermatitis	1.33e-05	0.000244	CcSEcCtD
Sirolimus—Tachycardia—Hydrocortisone—atopic dermatitis	1.33e-05	0.000243	CcSEcCtD
Sirolimus—MTOR—Insulin receptor signalling cascade—IL6—atopic dermatitis	1.33e-05	0.000833	CbGpPWpGaD
Sirolimus—MTOR—IGF1R signaling cascade—IL6—atopic dermatitis	1.33e-05	0.000833	CbGpPWpGaD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—atopic dermatitis	1.33e-05	0.000243	CcSEcCtD
Sirolimus—Skin disorder—Hydrocortisone—atopic dermatitis	1.32e-05	0.000242	CcSEcCtD
Sirolimus—Ill-defined disorder—Betamethasone—atopic dermatitis	1.32e-05	0.000242	CcSEcCtD
Sirolimus—Ill-defined disorder—Dexamethasone—atopic dermatitis	1.32e-05	0.000242	CcSEcCtD
Sirolimus—Discomfort—Triamcinolone—atopic dermatitis	1.32e-05	0.000242	CcSEcCtD
Sirolimus—MTOR—EGF/EGFR Signaling Pathway—MAPK8—atopic dermatitis	1.32e-05	0.00083	CbGpPWpGaD
Sirolimus—EIF4E—Cytokine Signaling in Immune system—IL6—atopic dermatitis	1.32e-05	0.000829	CbGpPWpGaD
Sirolimus—Discomfort—Methylprednisolone—atopic dermatitis	1.32e-05	0.000241	CcSEcCtD
Sirolimus—Hyperhidrosis—Hydrocortisone—atopic dermatitis	1.32e-05	0.000241	CcSEcCtD
Sirolimus—FGF2—Developmental Biology—PPARA—atopic dermatitis	1.32e-05	0.000826	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CXCR3—atopic dermatitis	1.31e-05	0.000822	CbGpPWpGaD
Sirolimus—Angioedema—Dexamethasone—atopic dermatitis	1.3e-05	0.000239	CcSEcCtD
Sirolimus—Angioedema—Betamethasone—atopic dermatitis	1.3e-05	0.000239	CcSEcCtD
Sirolimus—Anorexia—Hydrocortisone—atopic dermatitis	1.3e-05	0.000238	CcSEcCtD
Sirolimus—Nausea—Tacrolimus—atopic dermatitis	1.3e-05	0.000237	CcSEcCtD
Sirolimus—MTOR—Innate Immune System—TLR2—atopic dermatitis	1.3e-05	0.000815	CbGpPWpGaD
Sirolimus—MTOR—Immune System—KIF3A—atopic dermatitis	1.3e-05	0.000814	CbGpPWpGaD
Sirolimus—Angiopathy—Prednisone—atopic dermatitis	1.3e-05	0.000237	CcSEcCtD
Sirolimus—Confusional state—Methylprednisolone—atopic dermatitis	1.29e-05	0.000236	CcSEcCtD
Sirolimus—FGF2—Disease—SLC11A1—atopic dermatitis	1.29e-05	0.00081	CbGpPWpGaD
Sirolimus—Immune system disorder—Prednisone—atopic dermatitis	1.29e-05	0.000236	CcSEcCtD
Sirolimus—Malaise—Betamethasone—atopic dermatitis	1.29e-05	0.000235	CcSEcCtD
Sirolimus—Malaise—Dexamethasone—atopic dermatitis	1.29e-05	0.000235	CcSEcCtD
Sirolimus—Oedema—Triamcinolone—atopic dermatitis	1.28e-05	0.000235	CcSEcCtD
Sirolimus—Anaphylactic shock—Triamcinolone—atopic dermatitis	1.28e-05	0.000235	CcSEcCtD
Sirolimus—Anaphylactic shock—Methylprednisolone—atopic dermatitis	1.28e-05	0.000234	CcSEcCtD
Sirolimus—Syncope—Betamethasone—atopic dermatitis	1.28e-05	0.000234	CcSEcCtD
Sirolimus—Syncope—Dexamethasone—atopic dermatitis	1.28e-05	0.000234	CcSEcCtD
Sirolimus—Infection—Triamcinolone—atopic dermatitis	1.28e-05	0.000233	CcSEcCtD
Sirolimus—Hypotension—Hydrocortisone—atopic dermatitis	1.27e-05	0.000233	CcSEcCtD
Sirolimus—Infection—Methylprednisolone—atopic dermatitis	1.27e-05	0.000233	CcSEcCtD
Sirolimus—FGF2—Adaptive Immune System—CD8A—atopic dermatitis	1.27e-05	0.000799	CbGpPWpGaD
Sirolimus—FGF2—Signaling by SCF-KIT—IL6—atopic dermatitis	1.27e-05	0.000798	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCL17—atopic dermatitis	1.27e-05	0.000796	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—STAT6—atopic dermatitis	1.27e-05	0.000796	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—FCER2—atopic dermatitis	1.27e-05	0.000795	CbGpPWpGaD
Sirolimus—Shock—Triamcinolone—atopic dermatitis	1.26e-05	0.000231	CcSEcCtD
Sirolimus—Insomnia—Prednisolone—atopic dermatitis	1.26e-05	0.000231	CcSEcCtD
Sirolimus—Shock—Methylprednisolone—atopic dermatitis	1.26e-05	0.00023	CcSEcCtD
Sirolimus—Nervous system disorder—Methylprednisolone—atopic dermatitis	1.26e-05	0.00023	CcSEcCtD
Sirolimus—Loss of consciousness—Betamethasone—atopic dermatitis	1.26e-05	0.000229	CcSEcCtD
Sirolimus—Loss of consciousness—Dexamethasone—atopic dermatitis	1.26e-05	0.000229	CcSEcCtD
Sirolimus—Paraesthesia—Prednisolone—atopic dermatitis	1.25e-05	0.000229	CcSEcCtD
Sirolimus—Tachycardia—Triamcinolone—atopic dermatitis	1.25e-05	0.000229	CcSEcCtD
Sirolimus—Tachycardia—Methylprednisolone—atopic dermatitis	1.25e-05	0.000229	CcSEcCtD
Sirolimus—Skin disorder—Methylprednisolone—atopic dermatitis	1.24e-05	0.000228	CcSEcCtD
Sirolimus—Malnutrition—Prednisone—atopic dermatitis	1.24e-05	0.000227	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Hydrocortisone—atopic dermatitis	1.24e-05	0.000227	CcSEcCtD
Sirolimus—EIF4E—Signaling Pathways—IL5—atopic dermatitis	1.24e-05	0.000779	CbGpPWpGaD
Sirolimus—Hyperhidrosis—Triamcinolone—atopic dermatitis	1.24e-05	0.000227	CcSEcCtD
Sirolimus—Hyperhidrosis—Methylprednisolone—atopic dermatitis	1.24e-05	0.000226	CcSEcCtD
Sirolimus—ABCB1—Allograft Rejection—IFNG—atopic dermatitis	1.24e-05	0.000776	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—TNF—atopic dermatitis	1.24e-05	0.000775	CbGpPWpGaD
Sirolimus—Insomnia—Hydrocortisone—atopic dermatitis	1.23e-05	0.000226	CcSEcCtD
Sirolimus—Hypertension—Dexamethasone—atopic dermatitis	1.23e-05	0.000225	CcSEcCtD
Sirolimus—Hypertension—Betamethasone—atopic dermatitis	1.23e-05	0.000225	CcSEcCtD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—MAPK8—atopic dermatitis	1.23e-05	0.000773	CbGpPWpGaD
Sirolimus—Paraesthesia—Hydrocortisone—atopic dermatitis	1.22e-05	0.000224	CcSEcCtD
Sirolimus—FGF2—Downstream signaling of activated FGFR—IL6—atopic dermatitis	1.22e-05	0.000763	CbGpPWpGaD
Sirolimus—Myalgia—Dexamethasone—atopic dermatitis	1.22e-05	0.000222	CcSEcCtD
Sirolimus—Myalgia—Betamethasone—atopic dermatitis	1.22e-05	0.000222	CcSEcCtD
Sirolimus—Anxiety—Betamethasone—atopic dermatitis	1.21e-05	0.000221	CcSEcCtD
Sirolimus—Anxiety—Dexamethasone—atopic dermatitis	1.21e-05	0.000221	CcSEcCtD
Sirolimus—EIF4E—Gene Expression—PPARA—atopic dermatitis	1.21e-05	0.00076	CbGpPWpGaD
Sirolimus—Discomfort—Betamethasone—atopic dermatitis	1.2e-05	0.00022	CcSEcCtD
Sirolimus—Discomfort—Dexamethasone—atopic dermatitis	1.2e-05	0.00022	CcSEcCtD
Sirolimus—Dyspepsia—Hydrocortisone—atopic dermatitis	1.2e-05	0.000219	CcSEcCtD
Sirolimus—Hypotension—Methylprednisolone—atopic dermatitis	1.2e-05	0.000219	CcSEcCtD
Sirolimus—FGF2—Signaling by ERBB4—IL6—atopic dermatitis	1.2e-05	0.000751	CbGpPWpGaD
Sirolimus—MTOR—Senescence and Autophagy in Cancer—IL6—atopic dermatitis	1.19e-05	0.000749	CbGpPWpGaD
Sirolimus—Pain—Prednisolone—atopic dermatitis	1.19e-05	0.000218	CcSEcCtD
Sirolimus—Decreased appetite—Hydrocortisone—atopic dermatitis	1.19e-05	0.000217	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Hydrocortisone—atopic dermatitis	1.18e-05	0.000215	CcSEcCtD
Sirolimus—MTOR—Signaling Pathways—CCL22—atopic dermatitis	1.18e-05	0.000739	CbGpPWpGaD
Sirolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—atopic dermatitis	1.18e-05	0.000738	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CD79A—atopic dermatitis	1.17e-05	0.000735	CbGpPWpGaD
Sirolimus—Musculoskeletal discomfort—Triamcinolone—atopic dermatitis	1.17e-05	0.000214	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Methylprednisolone—atopic dermatitis	1.17e-05	0.000213	CcSEcCtD
Sirolimus—Pain—Hydrocortisone—atopic dermatitis	1.17e-05	0.000213	CcSEcCtD
Sirolimus—Oedema—Dexamethasone—atopic dermatitis	1.17e-05	0.000213	CcSEcCtD
Sirolimus—Oedema—Betamethasone—atopic dermatitis	1.17e-05	0.000213	CcSEcCtD
Sirolimus—Anaphylactic shock—Dexamethasone—atopic dermatitis	1.17e-05	0.000213	CcSEcCtD
Sirolimus—Anaphylactic shock—Betamethasone—atopic dermatitis	1.17e-05	0.000213	CcSEcCtD
Sirolimus—Insomnia—Triamcinolone—atopic dermatitis	1.16e-05	0.000212	CcSEcCtD
Sirolimus—Insomnia—Methylprednisolone—atopic dermatitis	1.16e-05	0.000212	CcSEcCtD
Sirolimus—Infection—Dexamethasone—atopic dermatitis	1.16e-05	0.000212	CcSEcCtD
Sirolimus—Infection—Betamethasone—atopic dermatitis	1.16e-05	0.000212	CcSEcCtD
Sirolimus—Ill-defined disorder—Prednisone—atopic dermatitis	1.15e-05	0.000211	CcSEcCtD
Sirolimus—Paraesthesia—Triamcinolone—atopic dermatitis	1.15e-05	0.000211	CcSEcCtD
Sirolimus—EIF4E—Metabolism of proteins—CXCL8—atopic dermatitis	1.15e-05	0.000723	CbGpPWpGaD
Sirolimus—Feeling abnormal—Prednisolone—atopic dermatitis	1.15e-05	0.00021	CcSEcCtD
Sirolimus—Paraesthesia—Methylprednisolone—atopic dermatitis	1.15e-05	0.00021	CcSEcCtD
Sirolimus—Anaemia—Prednisone—atopic dermatitis	1.15e-05	0.00021	CcSEcCtD
Sirolimus—ABCB1—Allograft Rejection—CXCL8—atopic dermatitis	1.15e-05	0.000721	CbGpPWpGaD
Sirolimus—Shock—Dexamethasone—atopic dermatitis	1.15e-05	0.00021	CcSEcCtD
Sirolimus—Shock—Betamethasone—atopic dermatitis	1.15e-05	0.00021	CcSEcCtD
Sirolimus—Dyspnoea—Triamcinolone—atopic dermatitis	1.15e-05	0.000209	CcSEcCtD
Sirolimus—FGF2—Downstream signal transduction—IL6—atopic dermatitis	1.14e-05	0.000717	CbGpPWpGaD
Sirolimus—Nervous system disorder—Betamethasone—atopic dermatitis	1.14e-05	0.000209	CcSEcCtD
Sirolimus—Nervous system disorder—Dexamethasone—atopic dermatitis	1.14e-05	0.000209	CcSEcCtD
Sirolimus—Agitation—Prednisone—atopic dermatitis	1.14e-05	0.000209	CcSEcCtD
Sirolimus—Thrombocytopenia—Dexamethasone—atopic dermatitis	1.14e-05	0.000209	CcSEcCtD
Sirolimus—Thrombocytopenia—Betamethasone—atopic dermatitis	1.14e-05	0.000209	CcSEcCtD
Sirolimus—FGF2—Signaling by FGFR—IL6—atopic dermatitis	1.14e-05	0.000714	CbGpPWpGaD
Sirolimus—Tachycardia—Dexamethasone—atopic dermatitis	1.14e-05	0.000208	CcSEcCtD
Sirolimus—Tachycardia—Betamethasone—atopic dermatitis	1.14e-05	0.000208	CcSEcCtD
Sirolimus—Angioedema—Prednisone—atopic dermatitis	1.14e-05	0.000208	CcSEcCtD
Sirolimus—FGF2—Signaling by ERBB2—IL6—atopic dermatitis	1.13e-05	0.00071	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—MAPK8—atopic dermatitis	1.13e-05	0.000709	CbGpPWpGaD
Sirolimus—Dyspepsia—Triamcinolone—atopic dermatitis	1.13e-05	0.000207	CcSEcCtD
Sirolimus—FGF2—Signaling Pathways—KIF3A—atopic dermatitis	1.13e-05	0.000709	CbGpPWpGaD
Sirolimus—Dyspepsia—Methylprednisolone—atopic dermatitis	1.13e-05	0.000206	CcSEcCtD
Sirolimus—FGF2—Immune System—CASP1—atopic dermatitis	1.13e-05	0.000707	CbGpPWpGaD
Sirolimus—Hyperhidrosis—Dexamethasone—atopic dermatitis	1.13e-05	0.000206	CcSEcCtD
Sirolimus—Hyperhidrosis—Betamethasone—atopic dermatitis	1.13e-05	0.000206	CcSEcCtD
Sirolimus—FGF2—DAP12 signaling—IL6—atopic dermatitis	1.13e-05	0.000707	CbGpPWpGaD
Sirolimus—Feeling abnormal—Hydrocortisone—atopic dermatitis	1.12e-05	0.000205	CcSEcCtD
Sirolimus—Malaise—Prednisone—atopic dermatitis	1.12e-05	0.000205	CcSEcCtD
Sirolimus—Gastrointestinal pain—Hydrocortisone—atopic dermatitis	1.12e-05	0.000204	CcSEcCtD
Sirolimus—Syncope—Prednisone—atopic dermatitis	1.12e-05	0.000204	CcSEcCtD
Sirolimus—Anorexia—Dexamethasone—atopic dermatitis	1.11e-05	0.000203	CcSEcCtD
Sirolimus—Anorexia—Betamethasone—atopic dermatitis	1.11e-05	0.000203	CcSEcCtD
Sirolimus—MTOR—Signaling by VEGF—IL6—atopic dermatitis	1.11e-05	0.000697	CbGpPWpGaD
Sirolimus—MTOR—Immune System—STAT6—atopic dermatitis	1.1e-05	0.000692	CbGpPWpGaD
Sirolimus—MTOR—Signaling by Insulin receptor—IL6—atopic dermatitis	1.1e-05	0.000692	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—IL1B—atopic dermatitis	1.1e-05	0.000692	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CCR3—atopic dermatitis	1.1e-05	0.00069	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—IL2—atopic dermatitis	1.1e-05	0.000689	CbGpPWpGaD
Sirolimus—Pain—Triamcinolone—atopic dermatitis	1.1e-05	0.000201	CcSEcCtD
Sirolimus—Loss of consciousness—Prednisone—atopic dermatitis	1.09e-05	0.0002	CcSEcCtD
Sirolimus—Hypotension—Betamethasone—atopic dermatitis	1.09e-05	0.000199	CcSEcCtD
Sirolimus—Hypotension—Dexamethasone—atopic dermatitis	1.09e-05	0.000199	CcSEcCtD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—atopic dermatitis	1.09e-05	0.000682	CbGpPWpGaD
Sirolimus—Body temperature increased—Hydrocortisone—atopic dermatitis	1.08e-05	0.000197	CcSEcCtD
Sirolimus—Abdominal pain—Hydrocortisone—atopic dermatitis	1.08e-05	0.000197	CcSEcCtD
Sirolimus—EIF4E—Immune System—NFKBIA—atopic dermatitis	1.08e-05	0.000676	CbGpPWpGaD
Sirolimus—Hypertension—Prednisone—atopic dermatitis	1.07e-05	0.000196	CcSEcCtD
Sirolimus—MTOR—Immune System—CARD11—atopic dermatitis	1.07e-05	0.000673	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL5—atopic dermatitis	1.07e-05	0.00067	CbGpPWpGaD
Sirolimus—Musculoskeletal discomfort—Dexamethasone—atopic dermatitis	1.06e-05	0.000194	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Betamethasone—atopic dermatitis	1.06e-05	0.000194	CcSEcCtD
Sirolimus—FGF2—Signaling by FGFR in disease—IL6—atopic dermatitis	1.06e-05	0.000665	CbGpPWpGaD
Sirolimus—FGF2—DAP12 interactions—IL6—atopic dermatitis	1.06e-05	0.000665	CbGpPWpGaD
Sirolimus—FGF2—Fc epsilon receptor (FCERI) signaling—IL6—atopic dermatitis	1.06e-05	0.000665	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CXCL10—atopic dermatitis	1.06e-05	0.000665	CbGpPWpGaD
Sirolimus—Myalgia—Prednisone—atopic dermatitis	1.06e-05	0.000194	CcSEcCtD
Sirolimus—Arthralgia—Prednisone—atopic dermatitis	1.06e-05	0.000194	CcSEcCtD
Sirolimus—Feeling abnormal—Triamcinolone—atopic dermatitis	1.06e-05	0.000193	CcSEcCtD
Sirolimus—Feeling abnormal—Methylprednisolone—atopic dermatitis	1.06e-05	0.000193	CcSEcCtD
Sirolimus—Anxiety—Prednisone—atopic dermatitis	1.06e-05	0.000193	CcSEcCtD
Sirolimus—Insomnia—Dexamethasone—atopic dermatitis	1.05e-05	0.000193	CcSEcCtD
Sirolimus—Insomnia—Betamethasone—atopic dermatitis	1.05e-05	0.000193	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Prednisone—atopic dermatitis	1.05e-05	0.000192	CcSEcCtD
Sirolimus—FGF2—Signaling by EGFR—IL6—atopic dermatitis	1.05e-05	0.000659	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCL27—atopic dermatitis	1.05e-05	0.000658	CbGpPWpGaD
Sirolimus—Gastrointestinal pain—Methylprednisolone—atopic dermatitis	1.05e-05	0.000192	CcSEcCtD
Sirolimus—Paraesthesia—Betamethasone—atopic dermatitis	1.05e-05	0.000191	CcSEcCtD
Sirolimus—Paraesthesia—Dexamethasone—atopic dermatitis	1.05e-05	0.000191	CcSEcCtD
Sirolimus—Discomfort—Prednisone—atopic dermatitis	1.05e-05	0.000191	CcSEcCtD
Sirolimus—FGF2—Signaling by EGFR in Cancer—IL6—atopic dermatitis	1.04e-05	0.000653	CbGpPWpGaD
Sirolimus—FGF2—Signaling by PDGF—IL6—atopic dermatitis	1.04e-05	0.00065	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GLB1—atopic dermatitis	1.03e-05	0.000646	CbGpPWpGaD
Sirolimus—Hypersensitivity—Prednisolone—atopic dermatitis	1.03e-05	0.000188	CcSEcCtD
Sirolimus—FGF2—Innate Immune System—NFKBIA—atopic dermatitis	1.03e-05	0.000645	CbGpPWpGaD
Sirolimus—Dyspepsia—Betamethasone—atopic dermatitis	1.03e-05	0.000188	CcSEcCtD
Sirolimus—Dyspepsia—Dexamethasone—atopic dermatitis	1.03e-05	0.000188	CcSEcCtD
Sirolimus—FGF2—Signaling Pathways—CCL11—atopic dermatitis	1.02e-05	0.000641	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CMA1—atopic dermatitis	1.02e-05	0.000641	CbGpPWpGaD
Sirolimus—FGF2—Immune System—TLR2—atopic dermatitis	1.02e-05	0.000639	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—CXCL8—atopic dermatitis	1.02e-05	0.000638	CbGpPWpGaD
Sirolimus—Body temperature increased—Triamcinolone—atopic dermatitis	1.02e-05	0.000186	CcSEcCtD
Sirolimus—Oedema—Prednisone—atopic dermatitis	1.01e-05	0.000186	CcSEcCtD
Sirolimus—Anaphylactic shock—Prednisone—atopic dermatitis	1.01e-05	0.000186	CcSEcCtD
Sirolimus—Abdominal pain—Methylprednisolone—atopic dermatitis	1.01e-05	0.000185	CcSEcCtD
Sirolimus—Decreased appetite—Dexamethasone—atopic dermatitis	1.01e-05	0.000185	CcSEcCtD
Sirolimus—Decreased appetite—Betamethasone—atopic dermatitis	1.01e-05	0.000185	CcSEcCtD
Sirolimus—Infection—Prednisone—atopic dermatitis	1.01e-05	0.000184	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Dexamethasone—atopic dermatitis	1.01e-05	0.000184	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Betamethasone—atopic dermatitis	1.01e-05	0.000184	CcSEcCtD
Sirolimus—Hypersensitivity—Hydrocortisone—atopic dermatitis	1e-05	0.000184	CcSEcCtD
Sirolimus—Shock—Prednisone—atopic dermatitis	9.99e-06	0.000183	CcSEcCtD
Sirolimus—Pain—Dexamethasone—atopic dermatitis	9.97e-06	0.000182	CcSEcCtD
Sirolimus—Pain—Betamethasone—atopic dermatitis	9.97e-06	0.000182	CcSEcCtD
Sirolimus—Nervous system disorder—Prednisone—atopic dermatitis	9.95e-06	0.000182	CcSEcCtD
Sirolimus—Tachycardia—Prednisone—atopic dermatitis	9.91e-06	0.000181	CcSEcCtD
Sirolimus—FGF2—Adaptive Immune System—NFKBIA—atopic dermatitis	9.87e-06	0.000619	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ADSL—atopic dermatitis	9.87e-06	0.000619	CbGpPWpGaD
Sirolimus—Skin disorder—Prednisone—atopic dermatitis	9.86e-06	0.00018	CcSEcCtD
Sirolimus—Hyperhidrosis—Prednisone—atopic dermatitis	9.81e-06	0.000179	CcSEcCtD
Sirolimus—FKBP1A—Signaling Pathways—NPS—atopic dermatitis	9.8e-06	0.000615	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TAC1—atopic dermatitis	9.8e-06	0.000615	CbGpPWpGaD
Sirolimus—Asthenia—Hydrocortisone—atopic dermatitis	9.79e-06	0.000179	CcSEcCtD
Sirolimus—EIF4E—Immune System—CASP8—atopic dermatitis	9.72e-06	0.00061	CbGpPWpGaD
Sirolimus—Anorexia—Prednisone—atopic dermatitis	9.67e-06	0.000177	CcSEcCtD
Sirolimus—Pruritus—Hydrocortisone—atopic dermatitis	9.65e-06	0.000176	CcSEcCtD
Sirolimus—FGF2—Signaling Pathways—STAT6—atopic dermatitis	9.61e-06	0.000603	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CXCR3—atopic dermatitis	9.61e-06	0.000603	CbGpPWpGaD
Sirolimus—Feeling abnormal—Betamethasone—atopic dermatitis	9.6e-06	0.000176	CcSEcCtD
Sirolimus—Feeling abnormal—Dexamethasone—atopic dermatitis	9.6e-06	0.000176	CcSEcCtD
Sirolimus—FGF2—Immune System—CD79A—atopic dermatitis	9.58e-06	0.000601	CbGpPWpGaD
Sirolimus—MTOR—Disease—SLC11A1—atopic dermatitis	9.58e-06	0.000601	CbGpPWpGaD
Sirolimus—Gastrointestinal pain—Dexamethasone—atopic dermatitis	9.53e-06	0.000174	CcSEcCtD
Sirolimus—Gastrointestinal pain—Betamethasone—atopic dermatitis	9.53e-06	0.000174	CcSEcCtD
Sirolimus—Hypersensitivity—Triamcinolone—atopic dermatitis	9.46e-06	0.000173	CcSEcCtD
Sirolimus—CYP3A7—Metabolism—GLB1—atopic dermatitis	9.45e-06	0.000593	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CD8A—atopic dermatitis	9.45e-06	0.000593	CbGpPWpGaD
Sirolimus—Hypersensitivity—Methylprednisolone—atopic dermatitis	9.44e-06	0.000173	CcSEcCtD
Sirolimus—MTOR—Signaling by SCF-KIT—IL6—atopic dermatitis	9.43e-06	0.000592	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCL17—atopic dermatitis	9.41e-06	0.000591	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—IL6—atopic dermatitis	9.39e-06	0.000589	CbGpPWpGaD
Sirolimus—Diarrhoea—Hydrocortisone—atopic dermatitis	9.33e-06	0.000171	CcSEcCtD
Sirolimus—FGF2—Innate Immune System—CASP8—atopic dermatitis	9.27e-06	0.000582	CbGpPWpGaD
Sirolimus—Musculoskeletal discomfort—Prednisone—atopic dermatitis	9.25e-06	0.000169	CcSEcCtD
Sirolimus—Dizziness—Prednisolone—atopic dermatitis	9.24e-06	0.000169	CcSEcCtD
Sirolimus—Asthenia—Triamcinolone—atopic dermatitis	9.22e-06	0.000168	CcSEcCtD
Sirolimus—Abdominal pain—Betamethasone—atopic dermatitis	9.21e-06	0.000168	CcSEcCtD
Sirolimus—Body temperature increased—Dexamethasone—atopic dermatitis	9.21e-06	0.000168	CcSEcCtD
Sirolimus—Abdominal pain—Dexamethasone—atopic dermatitis	9.21e-06	0.000168	CcSEcCtD
Sirolimus—Body temperature increased—Betamethasone—atopic dermatitis	9.21e-06	0.000168	CcSEcCtD
Sirolimus—Asthenia—Methylprednisolone—atopic dermatitis	9.19e-06	0.000168	CcSEcCtD
Sirolimus—Insomnia—Prednisone—atopic dermatitis	9.18e-06	0.000168	CcSEcCtD
Sirolimus—EIF4E—Signaling Pathways—CCL5—atopic dermatitis	9.12e-06	0.000572	CbGpPWpGaD
Sirolimus—Paraesthesia—Prednisone—atopic dermatitis	9.11e-06	0.000167	CcSEcCtD
Sirolimus—FKBP1A—Signaling Pathways—IL5—atopic dermatitis	9.11e-06	0.000572	CbGpPWpGaD
Sirolimus—Pruritus—Triamcinolone—atopic dermatitis	9.09e-06	0.000166	CcSEcCtD
Sirolimus—Pruritus—Methylprednisolone—atopic dermatitis	9.07e-06	0.000166	CcSEcCtD
Sirolimus—CYP3A7—Metabolism—ADSL—atopic dermatitis	9.06e-06	0.000568	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling of activated FGFR—IL6—atopic dermatitis	9.03e-06	0.000566	CbGpPWpGaD
Sirolimus—Dizziness—Hydrocortisone—atopic dermatitis	9.02e-06	0.000165	CcSEcCtD
Sirolimus—MTOR—Cellular responses to stress—MAPK8—atopic dermatitis	8.95e-06	0.000561	CbGpPWpGaD
Sirolimus—Dyspepsia—Prednisone—atopic dermatitis	8.93e-06	0.000163	CcSEcCtD
Sirolimus—MTOR—Signaling by ERBB4—IL6—atopic dermatitis	8.88e-06	0.000557	CbGpPWpGaD
Sirolimus—Decreased appetite—Prednisone—atopic dermatitis	8.82e-06	0.000161	CcSEcCtD
Sirolimus—Rash—Prednisolone—atopic dermatitis	8.81e-06	0.000161	CcSEcCtD
Sirolimus—Dermatitis—Prednisolone—atopic dermatitis	8.8e-06	0.000161	CcSEcCtD
Sirolimus—Diarrhoea—Methylprednisolone—atopic dermatitis	8.77e-06	0.00016	CcSEcCtD
Sirolimus—Headache—Prednisolone—atopic dermatitis	8.75e-06	0.00016	CcSEcCtD
Sirolimus—Constipation—Prednisone—atopic dermatitis	8.68e-06	0.000159	CcSEcCtD
Sirolimus—Vomiting—Hydrocortisone—atopic dermatitis	8.67e-06	0.000159	CcSEcCtD
Sirolimus—FKBP1A—Disease—CCR5—atopic dermatitis	8.6e-06	0.00054	CbGpPWpGaD
Sirolimus—Rash—Hydrocortisone—atopic dermatitis	8.6e-06	0.000157	CcSEcCtD
Sirolimus—Dermatitis—Hydrocortisone—atopic dermatitis	8.59e-06	0.000157	CcSEcCtD
Sirolimus—Headache—Hydrocortisone—atopic dermatitis	8.55e-06	0.000156	CcSEcCtD
Sirolimus—Dizziness—Triamcinolone—atopic dermatitis	8.49e-06	0.000155	CcSEcCtD
Sirolimus—MTOR—Downstream signal transduction—IL6—atopic dermatitis	8.48e-06	0.000532	CbGpPWpGaD
Sirolimus—Dizziness—Methylprednisolone—atopic dermatitis	8.47e-06	0.000155	CcSEcCtD
Sirolimus—EIF4E—Signaling Pathways—NGF—atopic dermatitis	8.44e-06	0.00053	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—IL6—atopic dermatitis	8.44e-06	0.00053	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—IL6—atopic dermatitis	8.4e-06	0.000527	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—MAPK8—atopic dermatitis	8.39e-06	0.000526	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KIF3A—atopic dermatitis	8.39e-06	0.000526	CbGpPWpGaD
Sirolimus—Feeling abnormal—Prednisone—atopic dermatitis	8.36e-06	0.000153	CcSEcCtD
Sirolimus—Asthenia—Betamethasone—atopic dermatitis	8.36e-06	0.000153	CcSEcCtD
Sirolimus—Asthenia—Dexamethasone—atopic dermatitis	8.36e-06	0.000153	CcSEcCtD
Sirolimus—MTOR—Immune System—CASP1—atopic dermatitis	8.36e-06	0.000525	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—IL6—atopic dermatitis	8.36e-06	0.000525	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCR3—atopic dermatitis	8.33e-06	0.000523	CbGpPWpGaD
Sirolimus—Gastrointestinal pain—Prednisone—atopic dermatitis	8.3e-06	0.000152	CcSEcCtD
Sirolimus—Nausea—Prednisolone—atopic dermatitis	8.3e-06	0.000152	CcSEcCtD
Sirolimus—EIF4E—Immune System—IFNG—atopic dermatitis	8.26e-06	0.000518	CbGpPWpGaD
Sirolimus—Pruritus—Betamethasone—atopic dermatitis	8.25e-06	0.000151	CcSEcCtD
Sirolimus—Pruritus—Dexamethasone—atopic dermatitis	8.25e-06	0.000151	CcSEcCtD
Sirolimus—EIF4E—Signaling Pathways—CCR5—atopic dermatitis	8.21e-06	0.000515	CbGpPWpGaD
Sirolimus—Vomiting—Triamcinolone—atopic dermatitis	8.17e-06	0.000149	CcSEcCtD
Sirolimus—Vomiting—Methylprednisolone—atopic dermatitis	8.15e-06	0.000149	CcSEcCtD
Sirolimus—Nausea—Hydrocortisone—atopic dermatitis	8.1e-06	0.000148	CcSEcCtD
Sirolimus—Rash—Triamcinolone—atopic dermatitis	8.1e-06	0.000148	CcSEcCtD
Sirolimus—Dermatitis—Triamcinolone—atopic dermatitis	8.09e-06	0.000148	CcSEcCtD
Sirolimus—Rash—Methylprednisolone—atopic dermatitis	8.08e-06	0.000148	CcSEcCtD
Sirolimus—Dermatitis—Methylprednisolone—atopic dermatitis	8.07e-06	0.000148	CcSEcCtD
Sirolimus—Headache—Triamcinolone—atopic dermatitis	8.05e-06	0.000147	CcSEcCtD
Sirolimus—Headache—Methylprednisolone—atopic dermatitis	8.03e-06	0.000147	CcSEcCtD
Sirolimus—Body temperature increased—Prednisone—atopic dermatitis	8.02e-06	0.000147	CcSEcCtD
Sirolimus—Abdominal pain—Prednisone—atopic dermatitis	8.02e-06	0.000147	CcSEcCtD
Sirolimus—ABCB1—Allograft Rejection—TNF—atopic dermatitis	8e-06	0.000502	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—CD4—atopic dermatitis	7.98e-06	0.000501	CbGpPWpGaD
Sirolimus—Diarrhoea—Dexamethasone—atopic dermatitis	7.97e-06	0.000146	CcSEcCtD
Sirolimus—Diarrhoea—Betamethasone—atopic dermatitis	7.97e-06	0.000146	CcSEcCtD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—atopic dermatitis	7.95e-06	0.000499	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL5—atopic dermatitis	7.93e-06	0.000497	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—IL6—atopic dermatitis	7.87e-06	0.000493	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—IL6—atopic dermatitis	7.87e-06	0.000493	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—atopic dermatitis	7.87e-06	0.000493	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL18—atopic dermatitis	7.84e-06	0.000492	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—IL6—atopic dermatitis	7.8e-06	0.000489	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CXCL10—atopic dermatitis	7.77e-06	0.000487	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—IL6—atopic dermatitis	7.73e-06	0.000485	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CD8A—atopic dermatitis	7.72e-06	0.000484	CbGpPWpGaD
Sirolimus—Dizziness—Dexamethasone—atopic dermatitis	7.71e-06	0.000141	CcSEcCtD
Sirolimus—Dizziness—Betamethasone—atopic dermatitis	7.71e-06	0.000141	CcSEcCtD
Sirolimus—MTOR—Signaling by PDGF—IL6—atopic dermatitis	7.69e-06	0.000483	CbGpPWpGaD
Sirolimus—Nausea—Triamcinolone—atopic dermatitis	7.63e-06	0.000139	CcSEcCtD
Sirolimus—MTOR—Innate Immune System—NFKBIA—atopic dermatitis	7.63e-06	0.000479	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—CD4—atopic dermatitis	7.61e-06	0.000478	CbGpPWpGaD
Sirolimus—Nausea—Methylprednisolone—atopic dermatitis	7.61e-06	0.000139	CcSEcCtD
Sirolimus—MTOR—Signaling Pathways—CMA1—atopic dermatitis	7.59e-06	0.000476	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCL11—atopic dermatitis	7.59e-06	0.000476	CbGpPWpGaD
Sirolimus—MTOR—Immune System—TLR2—atopic dermatitis	7.56e-06	0.000474	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	7.5e-06	0.000471	CbGpPWpGaD
Sirolimus—Hypersensitivity—Prednisone—atopic dermatitis	7.48e-06	0.000137	CcSEcCtD
Sirolimus—FGF2—Signaling Pathways—NPS—atopic dermatitis	7.43e-06	0.000466	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TAC1—atopic dermatitis	7.43e-06	0.000466	CbGpPWpGaD
Sirolimus—Vomiting—Dexamethasone—atopic dermatitis	7.41e-06	0.000135	CcSEcCtD
Sirolimus—Vomiting—Betamethasone—atopic dermatitis	7.41e-06	0.000135	CcSEcCtD
Sirolimus—ABCB1—Transmembrane transport of small molecules—SLC11A1—atopic dermatitis	7.37e-06	0.000463	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—IL1B—atopic dermatitis	7.37e-06	0.000462	CbGpPWpGaD
Sirolimus—Rash—Betamethasone—atopic dermatitis	7.35e-06	0.000134	CcSEcCtD
Sirolimus—Rash—Dexamethasone—atopic dermatitis	7.35e-06	0.000134	CcSEcCtD
Sirolimus—Dermatitis—Betamethasone—atopic dermatitis	7.34e-06	0.000134	CcSEcCtD
Sirolimus—Dermatitis—Dexamethasone—atopic dermatitis	7.34e-06	0.000134	CcSEcCtD
Sirolimus—EIF4E—Immune System—IL2—atopic dermatitis	7.34e-06	0.000461	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—NFKBIA—atopic dermatitis	7.33e-06	0.00046	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—CD4—atopic dermatitis	7.31e-06	0.000459	CbGpPWpGaD
Sirolimus—Headache—Betamethasone—atopic dermatitis	7.3e-06	0.000133	CcSEcCtD
Sirolimus—Headache—Dexamethasone—atopic dermatitis	7.3e-06	0.000133	CcSEcCtD
Sirolimus—FGF2—Signaling Pathways—CXCR3—atopic dermatitis	7.28e-06	0.000457	CbGpPWpGaD
Sirolimus—Asthenia—Prednisone—atopic dermatitis	7.28e-06	0.000133	CcSEcCtD
Sirolimus—FGF2—Signaling by NGF—IL6—atopic dermatitis	7.22e-06	0.000453	CbGpPWpGaD
Sirolimus—Pruritus—Prednisone—atopic dermatitis	7.18e-06	0.000131	CcSEcCtD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—atopic dermatitis	7.17e-06	0.00045	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—PPARA—atopic dermatitis	7.13e-06	0.000448	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—STAT6—atopic dermatitis	7.13e-06	0.000448	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CD79A—atopic dermatitis	7.11e-06	0.000446	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—atopic dermatitis	6.97e-06	0.000437	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—NFKBIA—atopic dermatitis	6.96e-06	0.000437	CbGpPWpGaD
Sirolimus—Diarrhoea—Prednisone—atopic dermatitis	6.94e-06	0.000127	CcSEcCtD
Sirolimus—Nausea—Betamethasone—atopic dermatitis	6.92e-06	0.000127	CcSEcCtD
Sirolimus—Nausea—Dexamethasone—atopic dermatitis	6.92e-06	0.000127	CcSEcCtD
Sirolimus—FGF2—Signaling Pathways—IL5—atopic dermatitis	6.91e-06	0.000433	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—CASP8—atopic dermatitis	6.88e-06	0.000432	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GLB1—atopic dermatitis	6.83e-06	0.000429	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—MAPK8—atopic dermatitis	6.76e-06	0.000424	CbGpPWpGaD
Sirolimus—Dizziness—Prednisone—atopic dermatitis	6.71e-06	0.000123	CcSEcCtD
Sirolimus—FKBP1A—Signaling Pathways—CCL5—atopic dermatitis	6.69e-06	0.00042	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ADSL—atopic dermatitis	6.55e-06	0.000411	CbGpPWpGaD
Sirolimus—FGF2—Disease—CCR5—atopic dermatitis	6.52e-06	0.000409	CbGpPWpGaD
Sirolimus—Vomiting—Prednisone—atopic dermatitis	6.45e-06	0.000118	CcSEcCtD
Sirolimus—FGF2—Innate Immune System—MAPK8—atopic dermatitis	6.45e-06	0.000405	CbGpPWpGaD
Sirolimus—Rash—Prednisone—atopic dermatitis	6.4e-06	0.000117	CcSEcCtD
Sirolimus—Dermatitis—Prednisone—atopic dermatitis	6.39e-06	0.000117	CcSEcCtD
Sirolimus—Headache—Prednisone—atopic dermatitis	6.36e-06	0.000116	CcSEcCtD
Sirolimus—FKBP1A—Signaling Pathways—NGF—atopic dermatitis	6.19e-06	0.000389	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCR3—atopic dermatitis	6.18e-06	0.000388	CbGpPWpGaD
Sirolimus—Nausea—Prednisone—atopic dermatitis	6.03e-06	0.00011	CcSEcCtD
Sirolimus—FKBP1A—Signaling Pathways—CCR5—atopic dermatitis	6.03e-06	0.000378	CbGpPWpGaD
Sirolimus—FGF2—Immune System—NFKBIA—atopic dermatitis	5.99e-06	0.000376	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CXCL10—atopic dermatitis	5.89e-06	0.000369	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL18—atopic dermatitis	5.82e-06	0.000365	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—TNF—atopic dermatitis	5.78e-06	0.000363	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CD8A—atopic dermatitis	5.73e-06	0.00036	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—IL6—atopic dermatitis	5.71e-06	0.000358	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—CD4—atopic dermatitis	5.65e-06	0.000355	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TAC1—atopic dermatitis	5.51e-06	0.000346	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NPS—atopic dermatitis	5.51e-06	0.000346	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CD4—atopic dermatitis	5.43e-06	0.00034	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CXCR3—atopic dermatitis	5.41e-06	0.000339	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—CD4—atopic dermatitis	5.4e-06	0.000339	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CASP8—atopic dermatitis	5.4e-06	0.000339	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—IL6—atopic dermatitis	5.36e-06	0.000336	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GLB1—atopic dermatitis	5.15e-06	0.000323	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL5—atopic dermatitis	5.12e-06	0.000322	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—NFKBIA—atopic dermatitis	5.11e-06	0.00032	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCL5—atopic dermatitis	5.07e-06	0.000318	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—atopic dermatitis	4.99e-06	0.000313	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CXCL8—atopic dermatitis	4.97e-06	0.000312	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ADSL—atopic dermatitis	4.94e-06	0.00031	CbGpPWpGaD
Sirolimus—MTOR—Disease—CCR5—atopic dermatitis	4.84e-06	0.000304	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—MAPK8—atopic dermatitis	4.79e-06	0.0003	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IL2—atopic dermatitis	4.75e-06	0.000298	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NGF—atopic dermatitis	4.69e-06	0.000295	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—IL6—atopic dermatitis	4.66e-06	0.000293	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IFNG—atopic dermatitis	4.59e-06	0.000288	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCR5—atopic dermatitis	4.57e-06	0.000286	CbGpPWpGaD
Sirolimus—MTOR—Immune System—NFKBIA—atopic dermatitis	4.44e-06	0.000279	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CD4—atopic dermatitis	4.44e-06	0.000278	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CXCL10—atopic dermatitis	4.37e-06	0.000274	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MAPK8—atopic dermatitis	4.37e-06	0.000274	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—IL6—atopic dermatitis	4.31e-06	0.000271	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—IL6—atopic dermatitis	4.12e-06	0.000258	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL1B—atopic dermatitis	4.1e-06	0.000257	CbGpPWpGaD
Sirolimus—FGF2—Disease—CD4—atopic dermatitis	4.09e-06	0.000257	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL2—atopic dermatitis	4.08e-06	0.000256	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CASP8—atopic dermatitis	4.01e-06	0.000251	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—atopic dermatitis	3.95e-06	0.000248	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NFKBIA—atopic dermatitis	3.87e-06	0.000243	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCL5—atopic dermatitis	3.76e-06	0.000236	CbGpPWpGaD
Sirolimus—FGF2—Immune System—MAPK8—atopic dermatitis	3.76e-06	0.000236	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CXCL8—atopic dermatitis	3.64e-06	0.000229	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—PPARA—atopic dermatitis	3.57e-06	0.000224	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NGF—atopic dermatitis	3.48e-06	0.000219	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IL2—atopic dermatitis	3.48e-06	0.000218	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IFNG—atopic dermatitis	3.41e-06	0.000214	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCR5—atopic dermatitis	3.39e-06	0.000213	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PPARA—atopic dermatitis	3.34e-06	0.00021	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CD4—atopic dermatitis	3.29e-06	0.000207	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MAPK8—atopic dermatitis	3.2e-06	0.000201	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GLB1—atopic dermatitis	3.18e-06	0.000199	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PPARA—atopic dermatitis	3.07e-06	0.000192	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—IL6—atopic dermatitis	3.06e-06	0.000192	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ADSL—atopic dermatitis	3.04e-06	0.000191	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL1B—atopic dermatitis	3.04e-06	0.000191	CbGpPWpGaD
Sirolimus—MTOR—Disease—CD4—atopic dermatitis	3.04e-06	0.000191	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL2—atopic dermatitis	3.03e-06	0.00019	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—IL6—atopic dermatitis	2.92e-06	0.000183	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NFKBIA—atopic dermatitis	2.87e-06	0.00018	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IL6—atopic dermatitis	2.79e-06	0.000175	CbGpPWpGaD
Sirolimus—MTOR—Immune System—MAPK8—atopic dermatitis	2.79e-06	0.000175	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CXCL8—atopic dermatitis	2.76e-06	0.000173	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL2—atopic dermatitis	2.64e-06	0.000166	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MAPK8—atopic dermatitis	2.43e-06	0.000152	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL6—atopic dermatitis	2.4e-06	0.00015	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PPARA—atopic dermatitis	2.22e-06	0.000139	CbGpPWpGaD
Sirolimus—FGF2—Disease—IL6—atopic dermatitis	2.21e-06	0.000139	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CXCL8—atopic dermatitis	2.05e-06	0.000129	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IL6—atopic dermatitis	2.05e-06	0.000128	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL2—atopic dermatitis	1.96e-06	0.000123	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MAPK8—atopic dermatitis	1.8e-06	0.000113	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL6—atopic dermatitis	1.78e-06	0.000112	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PPARA—atopic dermatitis	1.67e-06	0.000105	CbGpPWpGaD
Sirolimus—MTOR—Disease—IL6—atopic dermatitis	1.64e-06	0.000103	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL6—atopic dermatitis	1.55e-06	9.73e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL6—atopic dermatitis	1.15e-06	7.22e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PPARA—atopic dermatitis	1.03e-06	6.47e-05	CbGpPWpGaD
